Fax: (011) 49 30 450 55 39 32
A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer
Article first published online: 11 OCT 2007
Copyright © 2007 American Cancer Society
Volume 110, Issue 11, pages 2502–2506, 1 December 2007
How to Cite
Agaylan, A., Binder, D., Sauer, M., Neuweiler, H., Meyer, O., Kiesewetter, H. and Salama, A. (2007), A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer. Cancer, 110: 2502–2506. doi: 10.1002/cncr.23057
- Issue published online: 19 NOV 2007
- Article first published online: 11 OCT 2007
- Manuscript Revised: 14 JUN 2007
- Manuscript Accepted: 14 JUN 2007
- Manuscript Received: 3 MAY 2007
- Philip Morris USA Inc
- Philip Morris International
- enzyme-linked immunoadsorbent assay;
- p53 autoantibodies;
- p53 antibody detection
Numerous assays have been described for the detection of p53 autoantibodies. These assays are highly specific with low sensitivity. In this report, the authors describe a highly sensitive and simple particle agglutination immunoassay using superparamagnetic particles for capturing p5 autoantibodies, p53 protein, and p53 protein-antibody complexes from large volumes of serum samples (2 mL).
Superparamagnetic particles were coated with different peptides spanning the entire p53 protein. These particles were incubated with serum samples from healthy blood donors (n = 180), from patients without malignancies (n = 27), and from patients with various forms of lung cancer (n = 166). The particles were washed and placed into the reaction chamber of a gel card. After centrifugation, agglutination results were read visually. Positive reactions were defined by a layer of particles on top of the gel or agglutinated particles dispersed through the gel matrix.
Depending on the peptide used, p53 autoantibodies were detected in from 17.5% to 35% of the investigated patients with lung cancer. By using a commercially available enzyme-linked immunoadsorbent assay (ELISA) kit, p53 autoantibodies were detected in only 3% of those patients. P53 protein and p53 protein-antibody complexes were not detected in patients with lung cancer (n = 20).
The newly developed assay was easy to perform and had sensitivity superior to that of the currently available p53 ELISAs. Cancer 2007. © 2007 American Cancer Society.